Kangtai Biology (300601.SZ): Recombinant Hepatitis B Vaccine (Saccharomyces cerevisiae) (60 μg) New Applicants Program Receives Clinical Trial Approval

Zhitong Finance App News, Kangtai Biotech (300601.SZ) announced that the recombinant hepatitis B vaccine (Saccharomyces cerevisiae) (60 μg) newly applicable population project developed by the company obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration today. This product complies with the relevant requirements of drug registration and is approved to carry out clinical trials to prevent HBsAg recovery in people with functional (clinical) treatment of chronic hepatitis B.